Further Practical Guidance on Adjusting Time‐To‐Event Outcomes for Treatment Switching

The objective of this article is to bring together the key current information on practical considerations when conducting statistical analyses adjusting long-term outcomes for treatment switching, combining it with learnings from our own experience, thus providing a useful reference tool for analysts. When patients switch from their randomised treatment to another therapy that affects a subsequently observed outcome such as overall survival, there may be interest in estimating the treatment effect under a hypothetical scenario without the intercurrent event of switching. We describe the theory and provide guidance on how and when to conduct analyses using three commonly used complex approaches: rank preserving structural failure time models (RPSFTM), two-stage estimation (TSE), and inverse probability of censoring weighting (IPCW). Extensions and alternatives to the standard approaches are summarised. Important and sometimes misunderstood concepts such as recensoring and sources of variability are explained. An overview of available software and programming guidance is provided, along with an R code repository for a worked example, reporting recommendations, and a review of the current acceptability of these methods to regulatory and health technology assessment agencies. Since the current guidance on this topic is scattered across multiple sources, it is difficult for an analyst to obtain a good overview of all options and potential pitfalls. This paper is intended to save statisticians time and effort by summarizing important information in a single source. By also including recommendations for best practice, it aims to improve the quality of the analyses and reporting when adjusting time-to-event outcomes for treatment switching.

Authors

Institutions

Publication Details

Journal
Pharmaceutical Statistics
Published
2025-06-21
DOI
https://doi.org/10.1002/pst.70019
Citations
4
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
12.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Further Practical Guidance on Adjusting Time‐To‐Event Outcomes for Treatment Switching

Miguel A. Miranda, Claire Watkins, Eva Kleine, Orlando Doehring et al.
4 citations
Pharmaceutical Statistics
Health Systems, Economic Evaluations, Quality of Life
12.52
article

Further Practical Guidance on Adjusting Time‐To‐Event Outcomes for Treatment Switching

Miguel A. Miranda, Claire Watkins, Eva Kleine, Orlando Doehring, Emmanuel Bourmaud
article en
4 citations

Abstract

The objective of this article is to bring together the key current information on practical considerations when conducting statistical analyses adjusting long-term outcomes for treatment switching, combining it with learnings from our own experience, thus providing a useful reference tool for analysts. When patients switch from their randomised treatment to another therapy that affects a subsequently observed outcome such as overall survival, there may be interest in estimating the treatment effect under a hypothetical scenario without the intercurrent event of switching. We describe the theory and provide guidance on how and when to conduct analyses using three commonly used complex approaches: rank preserving structural failure time models (RPSFTM), two-stage estimation (TSE), and inverse probability of censoring weighting (IPCW). Extensions and alternatives to the standard approaches are summarised. Important and sometimes misunderstood concepts such as recensoring and sources of variability are explained. An overview of available software and programming guidance is provided, along with an R code repository for a worked example, reporting recommendations, and a review of the current acceptability of these methods to regulatory and health technology assessment agencies. Since the current guidance on this topic is scattered across multiple sources, it is difficult for an analyst to obtain a good overview of all options and potential pitfalls. This paper is intended to save statisticians time and effort by summarizing important information in a single source. By also including recommendations for best practice, it aims to improve the quality of the analyses and reporting when adjusting time-to-event outcomes for treatment switching.

Pharmaceutical StatisticsVol. 24(4)
AstraZeneca (United Kingdom) (GB), Boehringer Ingelheim (Germany) (DE)
Openalex Percentile: Top 2%
Health Systems, Economic Evaluations, Quality of Life
12.52
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.